Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Adverum’s mission is to strive to become the leader in gene medicine by developing novel drug therapies to transform the lives of patients with serious and rare diseases.

Adverum’s vision is to become the most advanced gene medicine company by pioneering treatments that improve and restore vision and other diseases through gene therapy.

Adverum has been the recipient of various awards and prestigious recognitions including: the 2016 BioSpace Company of the Week, the 2015-2016 Red Herring Top 100 Global Award and the 2014 Wall Street Journal’s Top 50 Venture-Backed Companies.